When was Novoheart founded?

Novoheart was founded in 2014 and raised its 1st funding round 4 years after it was founded.

Where is Novoheart located?

Novoheart is headquartered in Vancouver, Canada.

Who is the current CEO of Novoheart?

Ronald Li of Novoheart. They have also founded 1 company.

How many employees does Novoheart have?

As of Jun 30, 2026, the latest employee count at Novoheart is 17.

Is Novoheart a funded company?

Novoheart is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Feb 26, 2018.

When was the latest funding round of Novoheart?

Novoheart's latest funding was a $***** Grant (prize money) round on Jan 07, 2020, with participation from 1 investor.

Where does Novoheart rank among its competitors?

Novoheart ranks 5th amongst 21 active competitors, of which 4 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Quiver Bioscience, which secured an undisclosed amount in Apr, 2026.

Who are the top competitors of Novoheart?

Novoheart's top competitors include Quiver Bioscience, Forcyte Biotechnologies and Functional Fluidics. Among them, Quiver Bioscience secured the most recent funding round in April, 2026.

Novoheart - 2026 Company Profile, Team, Funding & Competitors

Company Details

Novoheart is dedicated to develop and engineer bioartificial human heart prototypes using a combination of stem cell and tissue engineering approaches. It has developed proprietary bioengineered human heart constructs which the company uses for drug discovery and development of heart therapeutics. Additionally, the company also offers screening and phenotyping services.

Website: novoheart.com
Social
Phone Number: +1 **********

Key Metrics

Founded Year

2014

Location

Vancouver, Canada

Stage

Acquired

Latest Funding Round

Grant (prize money), Jan 07, 2020, $*****

Investors

ITC

Ranked

5^th among 21 active competitors

Employee Count

17 as on Jun 30, 2026

Investment & Acquisitions

Xellera Therapeutics

Similar Companies

Quiver Bioscience & 23 more

Exit Details

Acquired

View Novoheart's full profile

Novoheart got acquired on Sep 16, 2020.

Click here to take a look at Novoheart's acquisition in detail

Novoheart has raised funding over 3 rounds. Its first funding round was on Feb 26, 2018. Its latest funding round was a Grant (prize money) round on Jan 07, 2020 for $*****. 1 investor participated in its latest round. Novoheart has 1 institutional investor.

Here is the list of recent funding rounds of Novoheart:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 07, 2020	7400764	Grant (prize money)	5744234	3866055	1700464	5384205
Jun 06, 2018	8381696	Grant (prize money)	3642548	3402307	1114177	ITC
Feb 26, 2018	3082965	Grant (prize money)	1272141	3376551	4786707	ITC

Access funding benchmarks and valuations. Sign up today!

View details of Novoheart's funding rounds and investors

The founders of Novoheart are TANG WAI and Ronald Li. Ronald Li is the CEO of Novoheart.

Here are the details of Novoheart's key team members:

TANG WAI: Director of Novoheart.
Ronald Li: Co-Founder & CEO of Novoheart.

View details of Novoheart's Founder profiles and Board Members

Novoheart's employee count trend

Novoheart has 17 employees as of Jun 26. Here is Novoheart's employee count trend over the years:

Uncover Novoheart's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Novoheart include Quiver Bioscience, Forcyte Biotechnologies and Functional Fluidics. Here is the list of Top 10 competitors of Novoheart, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Quiver Bioscience 2013, Cambridge (United States), Acquired	Developer of transformational medicines for neurological disorders	-	NIH, HHS	53/100
2nd	Forcyte Biotechnologies 2017, Los Angeles (United States), Seed	Developer of automated single-cell contractility screening system for drug discovery	$5.7M	Y Combinator, Acequia Capital & 4 others	44/100
3rd	Functional Fluidics 2013, Detroit (United States), Series A	Developer of microfluidics-based assays to study blood disorders	$3.58M	NYBC Ventures, Wavemaker 360 & 8 others	40/100
4th	MaxWell Biosystems 2016, Basel (Switzerland), Series A	Developer of an in vitro assay platform based on electrophysiology	$4.64M	Venture Kick, Sensirion & 3 others	40/100
5th	Novoheart 2014, Vancouver (Canada), Acquired	Tissue engineering tools for developing bioartificial heart	-	ITC	39/100
6th	Cytocybernetics 2013, Buffalo (United States), Funding Raised	Electrophysiology solutions: dynamic clamp, voltage-sensitive dyes, model builder, and analysis	-	43North, America’s Seed Fund & 1 others	34/100
7th	CellsBin 2022, New Haven (United States), Funding Raised	Developer of nanophotonic platforms for detecting and isolating rare cells	-	Connecticut Innovations	32/100
8th	Cellular Analytics 2019, Toronto (Canada), Unfunded	Developer of microfluidic platform for cell analytics	-	-	32/100
9th	Cambridge NeuroTech 2013, Cambridge (United Kingdom), Unfunded	Provider of electrophysiology-based solutions	-	-	31/100
10th	Nanion Technologies 2002, Munich (Germany), Funding Raised	Develops Automated patch clamp system	-	Europa	31/100